India’s pharmaceutical sector, valued at approximately $58 billion, is projected to grow to $120-130 billion by 2030 and reach $400-450 billion by 2047. The country is recognized as the “Pharmacy of the World,” supplying 20 percent of global generics and leading in vaccine exports, significantly impacting global healthcare.
Price Movement
With a market capitalization of Rs 15,712.50 crore, the shares of Blue Jet Healthcare Ltd closed at Rs 905.80 per share, decreased around 2.20 percent as compared to the previous closing price of Rs 926.20 apiece.
Brokerage Recommendations
Emkay Global, one of the well-known brokerages in India, gave a ‘Buy’ call on the Pharma stock with a target price of Rs 1,150 apiece, indicating a potential upside of 27 percent from Friday’s closing price of Rs 906.15 per share.
As per the brokerage, the company plans multiple new product launches, expanding existing lines, and developing advanced intermediates. Management remains focused on execution and sustaining strong growth across all verticals, including pharmaceuticals and contract media, ensuring long-term expansion and market leadership.
Financial oversight
Blue Jet has seen record Q3 earnings saw a 208 percent YoY surge in net profit to Rs 99 crore from Rs 32.1 crore. Revenue rose 90.9 percent YoY to Rs 318.4 crore, up from Rs 166.8 crore in Q3 FY24. Operationally, EBITDA grew 127 percent YoY to Rs 124 crore, while the EBITDA margin expanded by 630 basis points, reaching 39.9 percent from 32.7 percent in the previous year.
Mutual Fund Investment
Blue Jet is a part of portfolios of 13 mutual funds which include Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth, Groww Nifty Total Market Index Fund Regular Growth, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth, and others, holding a market value of about Rs 106 crore as of February 2025.
Capacity Expansion
The company expanded Unit 2 capacity, adding 120 KL (Phase 1) for cardiovascular intermediates and 37 KL (Phase 2) for contrast media. Commercial production for contrast media began in December 2024, aiming for full utilization by H1 FY26. Expansions align with customer contracts for efficiency.
Also read: Stock Under ₹15 jumps over 4% after receiving ₹10 Cr orders from Western Railway and others
Research & Development (R&D) Initiatives
The company is investing Rs 40 crores in R&D to advance intermediates, expand the contrast media portfolio, and enhance high-value CDMO capabilities. Strengthening R&D aims to reinforce its leadership position and accelerate product pipeline expansion for sustained growth in innovative healthcare solutions.
Remarkable Return
The stock has delivered multibagger returns of nearly 149.60 percent of returns in one year, and around 72.98 percent of positive returns in the last six months. So far in 2025, the shares of Blue Jet Healthcare Ltd has given positive returns of about 57.57 percent.
Company Profile
Blue Jet Healthcare specializes in pharmaceutical and healthcare ingredients. It focuses on products designed for pharmaceutical companies and generic pharmaceutical companies worldwide. Since its start in 1968, Blue Jet Healthcare has built a contract development and manufacturing organization (CDMO) business model
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
